动脉瘤性蛛网膜下腔出血后的镇痛药使用:基于人群的1187例病例对照研究
该研究纳入1995至2014年间在Kuopio大学医院收治的1187例囊状颅内动脉瘤破裂致蛛网膜下腔出血后存活12个月的患者,按年龄、性别和出生地匹配3561名对照。结果显示,患者组12个月内新启用镇痛药的比例为7.0%(83/1187),显著高于对照组的1.5%(53/3561),OR 5.0(95%CI 3.5-7.0,P<0.001),且新启用与脑内血肿独立相关。
要点
- 动脉瘤性蛛网膜下腔出血后12个月内,7.0%的患者新启用镇痛药,对照组仅1.5%。
- 病例组新启用镇痛药的OR为5.0(95%CI 3.5-7.0,P<0.001)。
- 脑内血肿与动脉瘤性蛛网膜下腔出血后12个月内新启用镇痛药独立相关。
核心结论
- 动脉瘤性蛛网膜下腔出血后存活12个月的患者,与匹配的对照人群相比,新发疼痛的风险增加。
研究设计与样本
- 基于人群的病例对照研究,纳入1995至2014年间在Kuopio大学医院收治的1187例囊状颅内动脉瘤破裂致蛛网膜下腔出血后存活12个月的患者,按年龄、性别和出生地1:3匹配3561名对照。
- 镇痛药数据来自芬兰社会保险机构全国处方药登记库,按解剖治疗化学分类系统分类。
主要发现
- 患者组83例(7.0%)在动脉瘤性蛛网膜下腔出血后12个月内新启用镇痛药,对照组53例(1.5%)新启用。
- 患者组12个月内新启用镇痛药的比例显著高于匹配对照人群,OR 5.0(95%CI 3.5-7.0,P<0.001)。
- 动脉瘤性蛛网膜下腔出血后12个月内新启用镇痛药与脑内血肿的存在独立相关。
- 患者组在动脉瘤性蛛网膜下腔出血后一年内新启用镇痛药的比例较出血前一年增加11%。
关键数值与推荐
- 患者组12个月内新启用镇痛药83/1187(7.0%),对照组53/3561(1.5%)。
- 新启用镇痛药的OR 5.0(95%CI 3.5-7.0,P<0.001)。
- 患者组新启用镇痛药比例在出血后一年较出血前一年增加11%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this population-based case-control study was to evaluate analgesic use after subarachnoid hemorrhage (SAH) caused by rupture of a saccular intracranial aneurysm (sIA). METHODS: The study consisted of 1187 patients alive 12 months after an sIA-SAH who were admitted to Kuopio University Hospital (KUH) between 1995 and 2014. Three controls, matched with age, sex, and birthplace, were included for each patient. Data on ruptured sIA cases admitted to KUH from a defined catchment population in Eastern Finland were obtained from the KUH intracranial aneurysm database. Analgesics were classified according to the Anatomical Therapeutic Chemical Classification system. Data on analgesic medication were retrieved from the Finnish national registry of prescribed medicines of the Social Insurance Institution of Finland. RESULTS: Among 1187 patients with sIA-SAH who were alive 12 months after admission, 83 (7.0%) commenced analgesics use within 12 months after the sIA-SAH versus 53 (1.5%) of the 3561 population controls. The results revealed significantly greater initiation rate of analgesic use among patients with sIA-SAH within a year after sIA-SAH as compared with that of matched population controls (odds ratio 5.0; 95% confidence interval 3.5-7.0; P < 0.001). Analgesic use commencement within 12 months of an sIA-SAH was independently associated with the presence of an intracerebral hematoma. Among patients, commencing analgesic use increased 11% when we compared a year before and a year after sIA-SAH. CONCLUSIONS: Our results indicate that patients with sIA-SAH had an increased risk for new pain after sIA-SAH as compared with that of matched control population.
引用
- Lindlöf M, Lindgren A, Paavola J, et al. Analgesic Use after Aneurysmal Subarachnoid Hemorrhage: A Population-Based Case-Control Study of 1187 Patients. World Neurosurg. 2019. PMID: 30898755. doi:10.1016/j.wneu.2019.02.241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。